Over the past two decades, clinical trials have become increasingly dependent upon image-based surrogate endpoints for evaluation of cancer therapeutics. The growing complexity of image-based response evaluation criteria has made it challenging for radiologists to provide reliable, timely, protocol-compliant longitudinal measurements.
The Tumor Imaging Metrics Core of the Dana-Farber/Harvard Cancer Center has improved the quality and efficiency of clinical trial imaging assessments by developing a software system, branded Precision Imaging Metrics (PIM), which is currently in use at six NCI-designated Cancer Centers. The PIM system consists of two integrated applications: a web-based workflow informatics management application and a desktop imaging application. PIM plans to extend their solution into Nucleus.io, an entirely cloud-based, widely deployable and easily supportable system with an integrated web-based image review tool. Nucleus will cloud-host the entire PIM oncology clinical trials platform, including DICOM image archive, new zero-footprint web-based image assessment viewer, and workflow/data management system.
The evolution of the system to a fully web-based, cloud-hosted deployment will enhance accessibility and reduce support requirements, decreasing costs and facilitating broader adoption. Adoption of the system at Cancer Centers nationwide will help ensure data quality and protocol compliance for cancer clinical research.
Gordon J. Harris, Ph.D. from Dana-Farber/Harvard Cancer Center, and Chris Hafey, CTO of NucleusHealth, presented the collaborative project in the Microsoft Innovation Theater at HIMSS ’17 in Orlando, FL.